Safety and efficacy of daratumumab in combination with bortezomib or lenalidomide plus dexamethasone in patients with relapsed/refractory multiple myeloma: GIMEMA Lazio group
Latest Information Update: 06 Apr 2021
At a glance
- Drugs Bortezomib (Primary) ; Daratumumab (Primary) ; Dexamethasone (Primary) ; Lenalidomide (Primary)
- Indications Multiple myeloma
- Focus Adverse reactions; Therapeutic Use
- 01 Apr 2021 Results (n=62) assessing efficacy and toxicity profile of daratumumab in relapsed or refractory multiple myeloma, published in the Annals of Hematology
- 20 Jul 2020 New trial record
- 21 Jun 2020 Results presented at the 25th Congress of the European Haematology Association